TY - JOUR T1 - Global quality of life in breast cancer: systematic review and meta-analysis JF - BMJ Supportive & Palliative Care JO - BMJ Support Palliat Care DO - 10.1136/bmjspcare-2022-003642 SP - bmjspcare-2022-003642 AU - Akbar Javan Biparva AU - Samira Raoofi AU - Sima Rafiei AU - Fatemeh Pashazadeh Kan AU - Mitra Kazerooni AU - Farzaneh Bagheribayati AU - Maryam Masoumi AU - Maryam Doustmehraban AU - Mohaddeseh Sanaei AU - Farnaz Zarabi AU - Neda Raoofi AU - Zahra Beiramy Chomalu AU - Behrooz Ahmadi AU - Fatemeh Seyghalani Talab AU - Batool Sadat Hoseini AU - Elnaz Asadollahi AU - Maryam Mir AU - Sama Deylami AU - Mahsa Zareei AU - Hadis Sanaei AU - Fateme Dousti nia Kakavand AU - Hooman Koohestani AU - Mahmoud Nasiri AU - Negin Vali AU - Ahmad Ghashghaee Y1 - 2022/06/16 UR - http://spcare.bmj.com/content/early/2022/08/21/bmjspcare-2022-003642.abstract N2 - Background Breast cancer (BC) is the most common cancer among women worldwide. We conducted a systematic review and meta-analysis to cover the existing research gap and contribute to existing knowledge to provide both researchers and clinicians with a better profile on the topic and consequently help improve the quality of life (QoL) of patients with BC.Methods A comprehensive review of original articles published in English from January 2000 to October 2021 from databases including Embase, Scopus, PubMed and Web of Science was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.Results Based on the meta-regression which examined a total of 9012 patients with BC, the QoL score calculated by EORTC QLQ-C30 was 64.72 (95% CI 59.24 to 70.20), while the score obtained from FACT-B was 84.39 (95% CI 64.24 to 104.54) and the scores from QLQ-BR23 and SF-36 were 66.33 (95% CI 62.76 to 69.90) and 57.23 (95% CI 47.65 to 66.82), respectively. A meta-analysis affirmed a significant direct relationship between the QoL score of patients with BC and their age (p=0.03). The results also revealed that the QoL scores of patients who had completed treatment were higher than those who were currently under treatment.Conclusion The present systematic review identified several factors that affect the QoL of women with BC worldwide and provided several implications for developing policy interventions to effectively improve the QoL of women with BC. In this way, clinicians can sufficiently give advice to their patients with the purpose of improving their QoL.PROSPERO registration number CRD42022309791. ER -